Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Goes Public, Shares Steeply Up on First Day of Trading

NEW YORK (GenomeWeb News) – Intrexon's shares were up as much as 69 percent on its first day of trading on the New York Stock Exchange today.

In afternoon trading, shares of the Germantown, Md.-based synthetic biology firm remained sharply up at 50 percent at $24.05.

It had priced its initial public offering of nearly 10 million shares at $16 per share, the upper end of an earlier anticipated price range. Intrexon also has granted underwriters a 30-day option to buy up to about 1.5 million additional shares of the company's stock. JP Morgan and Barclays are the joint book-running agents on the offering.

Intrexon's shares trade under ticker symbol "XON". The company filed to go public in early July.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.